Article

Court: J&J, Ocular Insight settle over contact lens ad claims

In response to a complaint filed in July by Johnson & Johnson Vision Care Inc., a U.S. district court in New York has ordered Ocular Insight Inc. to discontinue permanently stating or communicating in its advertising, promotional materials, or activities for the company's contact lenses (Clear 58) in the United States any of the following claims:

Jacksonville, FL and New York

-In response to a complaint filed in July by Johnson & Johnson (J&J) Vision Care Inc., a U.S. district court in New York has ordered Ocular Insight Inc. to discontinue permanently stating or communicating in its advertising, promotional materials, or activities for the company's contact lenses (Clear 58) in the United States any of the following claims:

  • Clear 58 is approved by the FDA.

  • Clear 58 is approved by the FDA as a generic equivalent lens to ACUVUE 2 brand contact lenses.

  • Clear 58 is a generic equivalent to ACUVUE 2.

  • Clear 58 is an exact duplicate or is identical to ACUVUE 2.

"In the interest of patient safety, we felt an urgent need to address these misleading claims as quickly as possible," said Naomi Kelman, president, Americas, Vistakon, Division of Johnson & Johnson Vision Care Inc. "While [the contact lens] has been 'cleared' for marketing by the FDA, it has not been 'approved' by the agency. Furthermore, the FDA does not perform the function of assessing whether a contact lens may be prescribed as a 'generic equivalent' lens."

On behalf of Ocular Insight, Mark Levin, the company's president, said, "Experience has led us to allow eye-care practitioners to determine if a contact lens made of the same material, same water content, same base curve, same diameter, and same method of manufacturing is a viable product to substitute for a branded product they currently dispense."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.